

FOSUN PHARMA
复星医药

2023



1

2

3

4

5

6



2023

1/2





® PD-1

- 1H23 5.56
- 3 ES-SCLC ES-SCLC
- PD-1
- 3 ES-SCLC MAA EMA
- 9 ESCC

®



®

®

®



•

•

•

•

•

•

•

•

-

-

-

-

-

-

-

-

-

-

-

-

-




CDE 2021 7



DRG/DIP






2019 - 2022

2023 - 2024


NDA/BLA

Ph3






Gland





MSCI-ESG


A






-


1



2,3



3



SCLC

PD-1



-
-
-
-
-
-
-
-



nature
medicine

IAAMA
Journal of the American Association of Medical Oncology

BJC
British Journal of Cancer



r/r LBCL

r/r LBCL

CAR-T

B

LBCL

LBCL

NHL

45.8%

NHL

LBCL 4

1.3

500

2023 6

140

25

10,000

GMP

2023 6

60

90

FL

MZL

2021 8

r/r FL

Kite Pharma

CAR-T



Tecartus™

2020 7

FDA

r/r ALL

MCL







—

1

1,2

1








1H23 /



BeautiFill™


- LipoSense™
- CellFie™









1



2,3



3



2011-2017

-
-
-
-

2018-2020

-
-
-
-

2021

-
-
-
-

6,448 * 9

JCI

1H23



600

2017 11 9.09
60%



800

900


2022 1 70%

2022 21.45 1.11
87.41%



*

2023 6



406,382

3Q22




445,920

3Q23



5,857



2,254





		®		
		®		
		®		
		®		
		®		

		®		
		®		
		®		
		®		
		®		
		®		

		⑧		
		⑨		
		⑩		
		⑪		

1/2

			/			IND	1	2	3	NDA
HLX10 ¹	+		PD-1	/	III 2022 11					
					2022 11 2022 FDA/EC 2023 1					
	+	+	PD-1		III 2023 1 2022 5					
	+		PD-1+VEGF		2022 1					
	+HLX07		PD-1+EGFR							
	+HLX07 +		PD-1+EGFR +VEGF							
HLX07		EGFR								
HLX22										
HLX11		2	HER2		III 2022					
HLX05		3	EGFR							
HLX02		4	HER2		FDA 2020					



[illegible]

1/2

		I			IND	1	2	3	NDA
FCN-437c		CDK4/6	1L						
			2L						
SAF-189		ALK/ROS1	ALK+		2022 1 NMPA III				
			ROS1+						
HLX-208	-	BRAF	Erdheim-Chester ECD LCH		2023 4 LCH ECD NMPA				
		BRAF+PD-1	BRAF V600E BRAF V600						
FCN-159		MEK	I		2023 7 NMPA			II	
					2023 4 NMPA		2022 5 NMPA		
YP01001		VEGFR			NMPA				
FCN-338		BCL-2			NMPA				
			B						
FH-2001		FGFR/PD-L1							
ORIN1001		IRE1							

2/2

		/			IND	1	2	3	NDA
		TPO-R	ITP						
	Tenapanor	NHE 3	(ESRD-HD)						
		P-CAB							
	Tenapanor	NHE 3	(IBS-C)						
	PA-824	-	XDR-TB / MDR-TB		Pretomanid*				
	Opicapone	COMT			Ongentys*				
	Fortacin	-			*				
	ET-26	-			2023 10	III			
	FCN-159	MEK							
	ORIN1001	IRE1							
	FCN-016	ROCK			2023 1	NMPA			
	SZEY-2108	-	CRE		2023 6	NMPA			

			IND	1	2	3	NDA
	/						
	/						
	/						
13							
24							
23							
	-						

-

-

-

FOSUN”

LOGO

- Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.
- The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.
- Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and other related logos, like “Fosun” and” , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.

FO SUN PHARMA



www.fosunpharma.com